Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$1,168.18 USD

1,168.18
807,039

+11.45 (0.99%)

Updated Sep 1, 2026 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 248)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?

by Kinjel Shah

Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

Sundeep Ganoria headshot

VKTX Stock Rises 34% in Three Months: Here's What You Should Know

by Sundeep Ganoria

Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.

Zacks Equity Research

Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Zacks Equity Research

Zacks Investment Ideas feature highlights Lilly

by Zacks Equity Research

Lilly have been highlighted in this Investment Ideas article.

Ahan Chakraborty headshot

Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?

by Ahan Chakraborty

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.

Zacks Equity Research

Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy

by Zacks Equity Research

NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.

Bryan Hayes headshot

Lilly's Moment: AI-Powered Pipeline Positions Shares to Surge in 2026

by Bryan Hayes

Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.

Zacks Equity Research

NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes

by Zacks Equity Research

Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.

Kinjel Shah headshot

AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights

by Kinjel Shah

ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.

Zacks Equity Research

Healthcare Equity ETF (GDOC) Hits Fresh 52-Week High

by Zacks Equity Research

GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.